Association between circulating adiponectin levels and polycystic ovarian syndrome

Saira Saeed Mirza, Kashif Shafique, Abdul Rauf Shaikh, Naveed Ali Khan, Masood Anwar Qureshi, Saira Saeed Mirza, Kashif Shafique, Abdul Rauf Shaikh, Naveed Ali Khan, Masood Anwar Qureshi

Abstract

Background: Low adiponectin levels in polycystic ovarian syndrome (PCOS) have been largely attributed to obesity which is common among these patients. In addition, evidence also suggests that low adiponectin in PCOS may be related to insulin resistance (IR) in these women. However, studies on the role of adiponectin in younger and lean patients are limited. Therefore, the aim of the present study was to examine the association of adiponectin levels in young and lean women with PCOS.

Methods: A case-control study was conducted at the Dow University of Health Sciences, Karachi, Pakistan. Cases were 75 patients of PCOS with Body Mass Index (BMI) &23 aged 16-35 years and 75 healthy age and BMI matched controls were selected from family and friends of the cases. Demographic details, family history and past medical history were obtained through interview by a physician. Anthropometric measurements included weight and height of the participants. Fasting glucose, total cholesterol, high-density lipoprotein (HDL), insulin, adiponectin, and androgen levels were determined. IR was calculated using homeostasis model assessment for insulin resistance (HOMA-IR). Logistic regression models were used to assess the association between adiponectin and PCOS after adjusting for co-variates.

Results: On multivariable analysis, PCOS cases were 3.2 times more likely to have low adiponectin level (OR = 3.2, 95% CI 1.49-6.90, p-value 0.003) compared to the controls after adjustment for age, BMI, family history, marital status, total cholesterol, HDL level and IR. Females with a family history of PCOS were significantly more likely to have lower adiponectin (OR = 3.32, 95% CI 1.27-8.67, p-value 0.014) compared to those who did not have a family history of PCOS. The associations of IR and family history with low adiponectin level also remained statistically significant after adjustments for covariates.

Conclusion: Serum adiponectin levels are independently associated with PCOS and are only partly explained by IR. Adiponectin level may serve as a potential independent biomarker for diagnosis of PCOS in young and lean women with fewer symptoms, or women with a family history of PCOS.

Figures

Figure 1
Figure 1
Age-specific relationship between PCOS and adiponectin level. Adjusted odds ratio are estimated after accounting for BMI, family history of PCOS, marital status, total cholesterol level, high density lipoprotein level and insulin resistance.

References

    1. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC. et al.Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297–307. doi: 10.1093/humupd/dmp006.
    1. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol. 1961;21:1440–1447. doi: 10.1210/jcem-21-11-1440.
    1. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007;88:1389–1395. doi: 10.1016/j.fertnstert.2007.01.032.
    1. Cho LW, Randeva HS, Atkin SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag. 2007;3:55–63.
    1. Handelsman Y. Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009;37:18–20. doi: 10.1177/0192623308329288.
    1. Vuguin PM. Interventional studies for polycystic ovarian syndrome in children and adolescents. Ped Health. 2010;4:59–73. doi: 10.2217/phe.09.69.
    1. Katulski K, Meczekalski B. Natural history of polycyclic ovary syndrome. Pol Merkur Lekarski. 2010;29:58–60.
    1. Liu X, Zhang J, Li Y, Xu L, Wei D, Qiu D. et al.On the relationship between serum total adiponectin and insulin resistance in polycystic ovary syndrome. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010;27:636–640.
    1. Vrbikova J, Dvorakova K, Hill M, Vcelak J, Stanicka S, Vankova M. et al.Determinants of circulating adiponectin in women with polycystic ovary syndrome. Gynecol Obstet Invest. 2005;60:155–161. doi: 10.1159/000086273.
    1. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K. et al.The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946. doi: 10.1038/90984.
    1. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. et al.Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935. doi: 10.1210/jcem.86.5.7463.
    1. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008;89:1200–1208. doi: 10.1016/j.fertnstert.2007.04.046.
    1. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91:781–785. doi: 10.1210/jc.2005-2153.
    1. World Health Organization-International Obesity Task Force. The Asia-pacific perspective: redefining obesity and its treatment. Health communications Australia. 2000. Accessed on 06-08-2013.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovarian syndrome. Fertil Steril. 2004;81:19–25.
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Harrison S, Somani N, Bergfeld WF. Update on the management of hirsutism. Cleve Clin J Med. 2010;77:388–98. doi: 10.3949/ccjm.77a.08079.
    1. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2005;83:1708–1716. doi: 10.1016/j.fertnstert.2004.11.077.
    1. Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K. et al.Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J Clin Endocrinol Metab. 2008;93:2859–2865. doi: 10.1210/jc.2007-2759.
    1. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM. et al.Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152:389–394. doi: 10.1530/eje.1.01868.
    1. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M. et al.Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006;21:2257–2265. doi: 10.1093/humrep/del146.
    1. Sepilian V, Nagamani M. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance. J Soc Gynecol Investig. 2005;12:129–134. doi: 10.1016/j.jsgi.2004.09.003.
    1. Wickham EP III, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism. 2011;60:366–72. doi: 10.1016/j.metabol.2010.02.019.
    1. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89–94. doi: 10.2337/diacare.24.1.89.
    1. Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M. et al.Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 2010;95:722–730. doi: 10.1210/jc.2009-1985.
    1. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670–2678. doi: 10.1210/jc.2008-0115.
    1. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A. et al.Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007;156:263–269. doi: 10.1530/eje.1.02331.
    1. Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann AP. et al.Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008;68:165–174.
    1. Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998;49:91–99. doi: 10.1046/j.1365-2265.1998.00492.x.
    1. Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update. 2001;7:3–7. doi: 10.1093/humupd/7.1.3.
    1. Sir-Petermann T, Maliqueo M, Codner E, Echiburu B, Crisosto N, Perez V. et al.Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:4637–4642. doi: 10.1210/jc.2007-1036.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren